MA41494B1 - Composés benzoxaborole substitués en position 4 et utilisations associées - Google Patents
Composés benzoxaborole substitués en position 4 et utilisations associéesInfo
- Publication number
- MA41494B1 MA41494B1 MA41494A MA41494A MA41494B1 MA 41494 B1 MA41494 B1 MA 41494B1 MA 41494 A MA41494 A MA 41494A MA 41494 A MA41494 A MA 41494A MA 41494 B1 MA41494 B1 MA 41494B1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds substituted
- associated uses
- benzoxaborole compounds
- ch2ch2ch3
- ch2ch3
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/04—Esters of boric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La présente invention concerne des benzoxaboroles substitués dont la structure comprend la formule (iii), dans laquelle r3 est choisi parmi –ch3, –ch2ch3, –ch2=ch2, –ch2ch2ch3, –ch(ch3)2, –ch2ch2=ch2, et un cyclopropyle, r1 et r2 sont chacun indépendamment choisis parmi h, -ch3, -ch2ch3, –ch2ch2ch3, et –ch(ch3)2 ; des compositions contenant de tels composés, leur utilisation en thérapie, y compris leur utilisation comme agents anti-mycobactériens, par exemple dans le traitement d'une infection mycobactérienne chez un mammifère, et des procédés pour la préparation de tels composés.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15382056 | 2015-02-12 | ||
| EP15382054 | 2015-02-12 | ||
| EP15382055 | 2015-02-12 | ||
| PCT/IB2016/050775 WO2016128948A1 (fr) | 2015-02-12 | 2016-02-12 | Composés benzoxaborole substitués en position 4 et utilisations associées |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA41494A MA41494A (fr) | 2017-12-19 |
| MA41494B1 true MA41494B1 (fr) | 2020-10-28 |
Family
ID=55409879
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA41494A MA41494B1 (fr) | 2015-02-12 | 2016-02-11 | Composés benzoxaborole substitués en position 4 et utilisations associées |
| MA041495A MA41495A (fr) | 2015-02-12 | 2016-02-11 | Composés benzoxaborole et leurs utilisations |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA041495A MA41495A (fr) | 2015-02-12 | 2016-02-11 | Composés benzoxaborole et leurs utilisations |
Country Status (36)
| Country | Link |
|---|---|
| US (3) | US10774096B2 (fr) |
| EP (2) | EP3256480A1 (fr) |
| JP (2) | JP2018506540A (fr) |
| KR (2) | KR20170117158A (fr) |
| CN (2) | CN107531730B (fr) |
| AU (3) | AU2016217507B2 (fr) |
| BR (2) | BR112017017213A2 (fr) |
| CA (2) | CA2976308A1 (fr) |
| CL (2) | CL2017002059A1 (fr) |
| CO (2) | CO2017008816A2 (fr) |
| CR (2) | CR20170372A (fr) |
| CY (1) | CY1123687T1 (fr) |
| DK (1) | DK3256479T3 (fr) |
| DO (2) | DOP2017000188A (fr) |
| EA (2) | EA036516B1 (fr) |
| ES (1) | ES2821951T3 (fr) |
| HR (1) | HRP20201597T1 (fr) |
| HU (1) | HUE051113T2 (fr) |
| IL (2) | IL253865A0 (fr) |
| LT (1) | LT3256479T (fr) |
| MA (2) | MA41494B1 (fr) |
| MX (2) | MX379057B (fr) |
| MY (1) | MY194004A (fr) |
| NZ (1) | NZ734379A (fr) |
| PE (2) | PE20171432A1 (fr) |
| PH (2) | PH12017501428A1 (fr) |
| PL (1) | PL3256479T3 (fr) |
| PT (1) | PT3256479T (fr) |
| RS (1) | RS60885B1 (fr) |
| SG (2) | SG11201706510YA (fr) |
| SI (1) | SI3256479T1 (fr) |
| SM (1) | SMT202000565T1 (fr) |
| TW (2) | TW201702250A (fr) |
| UA (1) | UA120527C2 (fr) |
| WO (2) | WO2016128949A1 (fr) |
| ZA (1) | ZA201705456B (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY175823A (en) * | 2013-08-09 | 2020-07-10 | Glaxosmithkline Ip No 2 Ltd | Tricyclic benzoxaborole compounds and uses thereof |
| HUE059818T2 (hu) * | 2017-05-08 | 2022-12-28 | Glaxosmithkline Intellectual Property Dev | Szenfetrinem vagy annak sója vagy észtere a mikrobakteriális fertõzés kezelésében való felhasználásra |
| EP3716766A4 (fr) | 2017-11-30 | 2021-12-22 | Boragen, Inc. | Composés de benzoxaborole et leurs formulations |
| EP3836938A4 (fr) | 2018-08-18 | 2022-05-11 | Boragen, Inc. | Formes solides de benzoxaborole substitué et compositions associées |
| CN110441344B (zh) * | 2019-06-25 | 2020-09-29 | 北京大学 | 一种基于固体核磁共振技术检测rna结构的方法 |
| AU2023287063A1 (en) * | 2022-06-23 | 2024-05-30 | Shanghai Micurx Pharmaceutical Co., Ltd. | Prodrugs of boron compounds and their use in treating bacterial infections |
| CN119233823A (zh) * | 2022-06-23 | 2024-12-31 | 上海盟科药业股份有限公司 | 硼化合物治疗非结核分枝杆菌感染的方法和用途及用于治疗相同疾病的药物组合物 |
| KR20240150582A (ko) | 2023-04-08 | 2024-10-15 | 김태서 | 맥세이프 배터리팩을 포함한 아이폰 케이스 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9411587D0 (en) * | 1994-06-09 | 1994-08-03 | Zeneca Ltd | Compound, composition and use |
| US6632955B1 (en) | 1996-12-02 | 2003-10-14 | Chisso Corporation | Optically active nitro alcohol derivatives, optically active amino alcohol derivatives, and process for preparing the same |
| AU2003298328A1 (en) | 2002-12-02 | 2004-06-23 | Solvias Ag | Catalytic hydrogeneration of carbon-heteroatom double bonds |
| KR101456815B1 (ko) | 2005-02-16 | 2014-10-31 | 아나코르 파마슈티칼스 인코포레이티드 | 보론함유 소분자 |
| JP5084717B2 (ja) | 2005-03-08 | 2012-11-28 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | キラル・ビスオキサゾリン触媒 |
| CN106008583A (zh) | 2005-12-30 | 2016-10-12 | 安纳考尔医药公司 | 含硼的小分子 |
| TWM325238U (en) * | 2006-12-29 | 2008-01-11 | Universal Scient Ind Co Ltd | Voltage regulator and voltage regulating system |
| KR100848491B1 (ko) | 2007-01-16 | 2008-07-28 | 영진약품공업주식회사 | 베타아미노기를 갖는 2-싸이아졸리딘 유도체, 이의약학적으로 허용 가능한 염 및 이의 제조 방법 |
| JO3396B1 (ar) | 2007-06-20 | 2019-10-20 | Anacor Pharmaceuticals Inc | جزيئات صغيرة تحتوي على البورون |
| CA2744231A1 (fr) | 2008-12-17 | 2010-07-15 | Anacor Pharmaceuticals, Inc. | Formes polymorphiques du (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo[c][1,2]oxaborol-1-ol |
| WO2011037731A1 (fr) * | 2009-09-25 | 2011-03-31 | Anacor Pharmaceuticals, Inc. | Petites molécules contenant du bore |
| ES2710105T3 (es) * | 2010-04-07 | 2019-04-23 | Glaxosmithkline Llc | Proceso para preparar benzoxaboroles |
| WO2012033858A2 (fr) * | 2010-09-07 | 2012-03-15 | Anacor Pharmaceuticals, Inc. | Petites molécules contenant du bore |
| CN104136032B (zh) * | 2011-12-22 | 2018-11-13 | 盟科医药技术公司 | 可用于抗菌治疗的三环类硼化合物 |
| CN102739587B (zh) | 2012-06-16 | 2014-05-21 | 天地融科技股份有限公司 | 音频数据传输方法 |
| KR101636431B1 (ko) | 2013-07-30 | 2016-07-05 | 동아에스티 주식회사 | 트리사이클릭 벤즈옥사보롤 화합물, 이의 제조방법 및 용도 |
| MY175823A (en) | 2013-08-09 | 2020-07-10 | Glaxosmithkline Ip No 2 Ltd | Tricyclic benzoxaborole compounds and uses thereof |
-
2016
- 2016-02-11 MA MA41494A patent/MA41494B1/fr unknown
- 2016-02-11 MA MA041495A patent/MA41495A/fr unknown
- 2016-02-12 LT LTEP16706002.9T patent/LT3256479T/lt unknown
- 2016-02-12 RS RS20201204A patent/RS60885B1/sr unknown
- 2016-02-12 CN CN201680021538.8A patent/CN107531730B/zh active Active
- 2016-02-12 CR CR20170372A patent/CR20170372A/es unknown
- 2016-02-12 BR BR112017017213-5A patent/BR112017017213A2/pt not_active Application Discontinuation
- 2016-02-12 SG SG11201706510YA patent/SG11201706510YA/en unknown
- 2016-02-12 DK DK16706002.9T patent/DK3256479T3/da active
- 2016-02-12 EA EA201791671A patent/EA036516B1/ru unknown
- 2016-02-12 JP JP2017542053A patent/JP2018506540A/ja active Pending
- 2016-02-12 ES ES16706002T patent/ES2821951T3/es active Active
- 2016-02-12 WO PCT/IB2016/050776 patent/WO2016128949A1/fr not_active Ceased
- 2016-02-12 MX MX2017010413A patent/MX379057B/es unknown
- 2016-02-12 JP JP2017541999A patent/JP6771472B2/ja active Active
- 2016-02-12 US US15/550,693 patent/US10774096B2/en active Active
- 2016-02-12 HR HRP20201597TT patent/HRP20201597T1/hr unknown
- 2016-02-12 UA UAA201708405A patent/UA120527C2/uk unknown
- 2016-02-12 NZ NZ734379A patent/NZ734379A/en not_active IP Right Cessation
- 2016-02-12 PE PE2017001400A patent/PE20171432A1/es not_active Application Discontinuation
- 2016-02-12 EP EP16706003.7A patent/EP3256480A1/fr not_active Withdrawn
- 2016-02-12 CA CA2976308A patent/CA2976308A1/fr not_active Abandoned
- 2016-02-12 CN CN201680021488.3A patent/CN107548398A/zh active Pending
- 2016-02-12 CA CA2976030A patent/CA2976030C/fr active Active
- 2016-02-12 MY MYPI2017702943A patent/MY194004A/en unknown
- 2016-02-12 CR CR20170371A patent/CR20170371A/es unknown
- 2016-02-12 EP EP16706002.9A patent/EP3256479B1/fr active Active
- 2016-02-12 EA EA201791667A patent/EA201791667A1/ru unknown
- 2016-02-12 PE PE2017001401A patent/PE20171348A1/es not_active Application Discontinuation
- 2016-02-12 SG SG11201706511TA patent/SG11201706511TA/en unknown
- 2016-02-12 US US15/550,658 patent/US20180037595A1/en not_active Abandoned
- 2016-02-12 AU AU2016217507A patent/AU2016217507B2/en not_active Ceased
- 2016-02-12 SM SM20200565T patent/SMT202000565T1/it unknown
- 2016-02-12 KR KR1020177025539A patent/KR20170117158A/ko not_active Ceased
- 2016-02-12 BR BR112017017211-9A patent/BR112017017211B1/pt active IP Right Grant
- 2016-02-12 PT PT167060029T patent/PT3256479T/pt unknown
- 2016-02-12 PL PL16706002T patent/PL3256479T3/pl unknown
- 2016-02-12 AU AU2016217508A patent/AU2016217508A1/en not_active Abandoned
- 2016-02-12 MX MX2017010414A patent/MX2017010414A/es unknown
- 2016-02-12 WO PCT/IB2016/050775 patent/WO2016128948A1/fr not_active Ceased
- 2016-02-12 HU HUE16706002A patent/HUE051113T2/hu unknown
- 2016-02-12 SI SI201630941T patent/SI3256479T1/sl unknown
- 2016-02-12 KR KR1020177025535A patent/KR20170117156A/ko not_active Withdrawn
- 2016-02-15 TW TW105104422A patent/TW201702250A/zh unknown
- 2016-02-15 TW TW105104376A patent/TWI730953B/zh not_active IP Right Cessation
-
2017
- 2017-08-07 IL IL253865A patent/IL253865A0/en unknown
- 2017-08-07 IL IL253864A patent/IL253864B/en unknown
- 2017-08-09 PH PH12017501428A patent/PH12017501428A1/en unknown
- 2017-08-09 PH PH12017501427A patent/PH12017501427A1/en unknown
- 2017-08-10 DO DO2017000188A patent/DOP2017000188A/es unknown
- 2017-08-10 DO DO2017000189A patent/DOP2017000189A/es unknown
- 2017-08-11 CL CL2017002059A patent/CL2017002059A1/es unknown
- 2017-08-11 CL CL2017002060A patent/CL2017002060A1/es unknown
- 2017-08-11 ZA ZA201705456A patent/ZA201705456B/en unknown
- 2017-08-29 CO CONC2017/0008816A patent/CO2017008816A2/es unknown
- 2017-08-29 CO CONC2017/0008809A patent/CO2017008809A2/es unknown
-
2020
- 2020-09-11 US US17/018,301 patent/US11214582B2/en active Active
- 2020-10-14 AU AU2020256369A patent/AU2020256369A1/en not_active Abandoned
- 2020-10-15 CY CY20201100978T patent/CY1123687T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA41494A (fr) | Composés benzoxaborole substitués en position 4 et utilisations associées | |
| MA41134A (fr) | Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales | |
| MA41625A (fr) | Composés de benzazépine dicarboxamide | |
| MA38227A1 (fr) | Nouveaux composés bicycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de ?-lactamase | |
| MA30232B1 (fr) | Inhibiteurs de kinase bases sur l'hydantoine | |
| MA52486B1 (fr) | Pyridazinones utilisés en tant qu'inhibiteurs de parp7 | |
| MA53124B1 (fr) | Agents de dégradation sélectifs des récepteurs des oestrogènes | |
| MA39211B1 (fr) | Composés tricycliques comme agents anti-cancers | |
| MA33745B1 (fr) | Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes | |
| MA46038B1 (fr) | Composés de sulfonimidoylpurinone substitués dans la position 7 pour le traitement et la prophylaxie d'infection virale | |
| MA38284A1 (fr) | Inhibiteurs de la phospholipase associée aux lipoprotéines a2 (lp-pla2) à base de 2,3-dihydro-imidazol[1,2-c]pyrimidin-5(1 h)-one | |
| MA45888A1 (fr) | Inhibiteurs de tyrosine kinase de bruton | |
| MA34361B1 (fr) | Dérivés de tétrahydro-pyrido-pyrimidine | |
| MA37762A1 (fr) | Composés n-aryltriazole utilisés comme antagonistes de lpar | |
| TN2016000188A1 (fr) | Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs. | |
| MA37764A1 (fr) | Composés n-alkyltriazole utilisés comme antagonistes de lpar | |
| MA34331B1 (fr) | Composés pyrazole comme inhibiteurs du récepteur sigma | |
| EP2091328A4 (fr) | Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer | |
| MA35748B1 (fr) | Fluorométhyl-5,6-dihydro-4h-[1,3]oxazines | |
| WO2019007696A1 (fr) | Nouveaux composés et compositions pharmaceutiques de ceux-ci destinés au traitement de la fibrose | |
| MA37439B1 (fr) | Inhibiteurs de dgat1 à ponts éthers cycliques pour le traitement de troubles medies par l'acyle coa-diacylglycerol transferase 1 (dgat1). | |
| MA31366B1 (fr) | Derives d'azetidine et leur utilisation comme antagonistes de prostaglandine e2 | |
| SA522441650B1 (ar) | مثبطات فوسفوينوسيتيد 3-كيناز الموضعية | |
| MA27629A1 (fr) | Dérivés du benzènesulfonamide, leur procédé de préparation et leur utilisation pour le traitement de la douleur. | |
| MA70477B1 (fr) | Composés amido hétéroaromatiques utiles dans le traitement de maladies hépatiques |